| 1. |
- Awan, Ahmed Arslan Yousuf, et al.
(författare)
-
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline
- 2023
-
Ingår i: Annals of Internal Medicine. - : AMER COLL PHYSICIANS. - 0003-4819 .- 1539-3704. ; 176, s. 1648-1655
-
Tidskriftsartikel (refereegranskat)abstract
- Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease (CKD) is an update of the 2018 guideline from KDIGO.Methods: The KDIGO Work Group (WG) updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and used expert judgment to develop recommendations. New evidence led to updating of recommendations in the chapters on treatment of hepatitis C virus (HCV) infection in patients with CKD (Chapter 2), management of HCV infection before and after kidney transplant (Chapter 4), and diagnosis and management of kidney disease associated with HCV infection (Chapter 5). Recommendations in chapters on detection and evaluation of hepatitis C in CKD (Chapter 1) and prevention of HCV transmission in hemodialysis units (Chapter 3) were not updated because of an absence of significant new evidence.Recommendations: The 2022 updated guideline includes 43 graded recommendations and 20 ungraded recommendations, 7 of which are new or modified on the basis of the most recent evidence and consensus among the WG members. The updated guidelines recommend expanding treatment of hepatitis C with sofosbuvir-based regimens to patients with CKD glomerular filtration rate categories G4 and G5, including those receiving dialysis; expanding the donor pool for kidney transplant recipients by accepting HCV-positive kidneys regardless of the recipient's HCV status; and initiating direct-acting antiviral treatment of HCV-infected patients with clinical evidence of glomerulonephritis without requiring kidney biopsy. The update also addresses the use of immunosuppressive regimens in such patients.
|
|
| 2. |
- Martin, Paul, et al.
(författare)
-
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
- 2022
-
Ingår i: Kidney International. - : ELSEVIER SCIENCE INC. - 0085-2538 .- 1523-1755. ; 102:6, s. 1228-1237
-
Tidskriftsartikel (refereegranskat)abstract
- Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.
|
|
| 3. |
- Pitz-Paal, Robert, et al.
(författare)
-
Concentrating solar power in Europe, the Middle East and North Africa: a review of development issues and potential to 2050
- 2012
-
Ingår i: Journal of Solar Energy Engineering, Transactions of the ASME. - : ASME International. - 1528-8986 .- 0199-6231. ; 134:2, s. Article Number: 024501-
-
Forskningsöversikt (refereegranskat)abstract
- This paper summarizes the findings of a study undertaken by the European Academies Science Advisory Council to evaluate the development challenges of concentrating solar power (CSP) and its consequent potential to contribute to low carbon electricity systems in Europe, the Middle East and North Africa (the MENA region) to 2050. The study reviewed the current status and prospective developments of the four main CSP technology families, and identified prospective technical developments, quantifying anticipated efficiency improvements and cost reductions. Similarly, developments in thermal energy storage were evaluated, and the role and value of CSP storage in electricity systems were examined. A key conclusion was that as the share of intermittent renewables in an electricity system increases, so does the value of thermal energy storage in CSP plants. Looking ahead, the study concludes that CSP should be cost competitive with fossil-fired power generation at some point in the 2020's provided that commercial deployment continues at an increasing rate, and through support mechanisms that incentivise technology development. Incentive schemes should reflect the real value of electricity to the system, and should ensure sufficient transparency of cost data that learning rates can be monitored. Key factors which will determine CSP's contribution in Europe and the MENA region over the period to 2050 are generating costs, physical constraints on construction of new plants and transmission, and considerations of security of supply. The study makes recommendations to European and MENA region policy makers on how the associated issues should be addressed.
|
|
